Previous studies have shown its expression alterations in breast cancer (Cekin et al., 2020) and identified that serum or plasma FGF23 concentrations are elevated in patients with advanced stage epithellal ovarian cancer (Tebben et al., 2005). Here, FGF23 is linked to breast carcinoma.